Breakthrough T1D Blog

JDRF Canada consulted a panel of Canadian endocrinologists to provide answers to some of your most frequently asked questions.

I have been blown away by the strength, resilience and generosity demonstrated by you, our JDRF family. I am reminded of how privileged we are to have your continued support.

March 24, 2020 Sponsored Content by Ei Lilly Canada  Eli Lilly Canada is pleased to announce the approval and availability of BaqsimiTM, a new rescue treatment for severe hypoglycemia, demonstrating […]

Drs. Ahmad Haidar, Laurent Legault, Michael Tsoukas and Jean-Franҫois Yale are a team of JDRF-funded researchers at McGill University (Montreal) who are the first to test the addition of pramlintide (a synthetic form of amylin, which is a hormone co-secreted with insulin by the healthy pancreas) to an artificial pancreas system – a combined treatment they hypothesize would help patients achieve optimal glucose control during the day.

We’re so happy to share our 8 finalists with you – meet our 2020 Manitoba Lobby Day Delegates!

JDRF President and CEO Dave Prowten testified recently in front of the Standing Committee on Finance as part of their 2020 Pre-Budget Consultations. Also appearing on JDRF’s behalf was Angie Sullivan, parent of a child with type 1 diabetes (T1D).

She was the youngest person in the room, and her presentation was met with resounding applause from the entire audience. Fourteen-year old Anne Pettigrew made an impressive and compelling presentation at last month’s Ontario pre-budget consultations in Scarborough.

Fifteen-year-old Kamilla Kozuback recalls fighting back tears as she successfully landed her final jump at the 2020 Youth Olympic Games this past January, placing eighth as one of the youngest snowboarders in the competition to ever represent Canada.

Now that 2019 has drawn to a close, we want to take a moment and extend our sincere thanks and appreciation for your support of our efforts in finding cures for type 1 diabetes (T1D) and improving the lives of the more than 300,000 Canadians and their families touched by this disease.

Dr. Suheda Erener is currently investigating whether micro-RNAs – a family of single-stranded molecules which are key regulators of gene expression and beta cell function – can predict the development of T1D.

Sernova Corp., a regenerative medicine company based in London, ON., has shown in its JDRF-funded clinical trial that its cell replacement therapy, Cell PouchTM, can restore insulin production among people living with T1D.

This month, twenty years ago, a pioneering clinical trial in Alberta marked a major advancement in islet transplantation for the treatment of type 1 diabetes (T1D).